Gero

• Alex Kadet

  Chief Business Officer

• Eileen Brandenburger

  Head of Intellectual Property and Licensing

• Olga Burmistrova

  Preclinical Program Lead

• Paulette Greenidge

  Program Lead, Medicinal Chemistry

• Michael Winther

  Head of Functional Genomics

• Amir Feizi

  Head of Translational AI and Discovery

• Aleksandr Sviridov

  Chief Operating Officer

• Max Kholin

  Co-founder and Chief Corporate Development Officer

• Peter Fedichev

  CEO and co-founder

• Konstantin Avchaciov

• Salih Tuna

• Liza Lopatina

• Arina Nikolskaya

• Klim Kostiuk

• Kirill Denisov

• Semyon Matrenok

• Ekaterina Melnikova

• Daniel Igumnov

• Maxim Kholin

• Simon S. Matrenok

Sources: gero.ai, doi.org

• Peter Fedichev

• Max Kholin

Sources: gero.ai

• Yuri Melnichek

  Board director

• Brian Kennedy

  Independent Director

Sources: gero.ai

• Jan Gruber

  Adviser, Associate Professor at the National University of Singapore

• Juan Pedro Bolaños Hernández

  Adviser, Professor at The University of Salamanca

• Mark Flanagan

  Adviser, Medicinal Chemistry at Pfizer, Co-inventor of XELJANZ and CIBINQO

• Nick Camp

  Adviser

• Bryn Williams-Jones

  Adviser, Founder and COO at Connected Discovery Ltd., Ex SVP of Drug Discovery at Benevolent AI.

Sources: gero.ai

• Singapore

Sources: biospace.com

• Series B

  US$17m, 19 Jun 2026

• Venture

  US$6m, 18 Oct 2023

• Series A

  US$2.2m, 5 Aug 2020

Sources: news.google.com, gero.ai